Physician profile
Ellen L Pratt
NPI 1255421533
$73,355.81
in general payments reported to CMS, 2019-2025
14 companies · $5,936 in 2025
The $5,936 reported for 2025 was more than what 85% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $17K · 2021: $330 · 2022: $925 · 2023: $12K · 2024: $6,986 · 2025: $5,936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Consulting Fee: $4,257 · Travel and Lodging: $4,058 · Food and Beverage: $2,308 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,875.00 |
| Consulting Fee | $4,257.00 |
| Travel and Lodging | $4,058.09 |
| Food and Beverage | $2,308.28 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $71,946.74 | 2019-2025 | Hizentra, Andembry, Haegarda |
| Genzyme Corporation | $431.30 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $153.08 | 2024-2025 | Dupixent |
| Glaxosmithkline, LLC. | $140.34 | 2024-2025 | Nucala, Trelegy Ellipta |
| Abbvie INC. | $136.33 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $107.07 | 2024-2025 | Airsupra, Tezspire, Fasenra |
| Novartis Pharmaceuticals Corporation | $103.26 | 2025 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2024 | |
| Ars Pharmaceuticals Operations, INC. | $69.19 | 2025 | Neffy |
| Alk-Abello, INC | $67.96 | 2020 | |
| Genentech USA, INC. | $41.88 | 2025 | Xolair |
| Lilly USA, LLC | $24.60 | 2025 | Ebglyss |
| Takeda Pharmaceuticals U.S.A., INC. | $20.04 | 2025 | Cuvitru |
| Verona Pharma, INC. | $14.07 | 2025 | Ohtuvayre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Pratt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.